0.76 USD
▼-0.02-2.33%
盘后 0.76 0.00%
2026-11-20
市值
$9.01M
市盈率
—
EPS
-0.23
股息率
—
52 周区间
0.68 – 2.12
成交量
15.05K
Beta
0.02
目标价
—
52W 低 0.6852W 高 2.12
价格走势
公司简介
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company’s lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural ...